Table 9.
Mouse PK data of 26a
Route | Cmax (ng/mL) | Tmax (h) | AUC (h*ng/mL) | T1/2 (h) | MRT (h) | CL (mL/min/Kg) | Vss (L/Kg) | F (%) |
---|---|---|---|---|---|---|---|---|
IV | 2757 | ND | 720 | 0.5 | 0.43 | 23.0 | 0.59 | ND |
PO | 223 | 0.25 | 396 | 0.79 | 1.51 | ND | ND | 5.49 |
IP | 5121 | 0.08 | 5718 | 4.52 | ND | ND | ND | ND |
C57BL/6 male mouse was dosed at 1 mg/Kg for the intravenous (IV), 10 mg/Kg for the oral (PO) and 10 mg for the intraperitineal (IP) studies. I. formulation used 10% N-Methyl pyrrolidone (NMP) and 50% polyethylene glycol (PEG-200) in water. P.O. formulation used 0.5% w/v NaCMC with 0.1% w/v Tween-80. IP administration formulation was 10% v/v dimethylacetimate (DMA); 20% v/v polyethylene glycol (PEG-200); 20% v/v PG in water